Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents

Fig. 3

Changes in SBP, BMI, and ePV from baseline to week 24 in the subgroups stratified by the baseline use of glucose-lowering agents. A The group differences (canagliflozin—glimepiride) of changes from baseline to week 24 (* refers to the naïve subgroup). The data are expressed as mean (95% confidence interval). B Absolute changes from baseline to week 24 after canagliflozin treatment († refers to the naïve subgroup). BMI body mass index, DPP-4 dipeptidyl peptidase-4, ePV estimated plasma volume, SBP systolic blood pressure

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840